How to buy InflaRx N-V stock

InflaRx N.V. is a biotechnology business based in the US. InflaRx N-V shares (IFRX) are listed on the NASDAQ and all prices are listed in US Dollars. InflaRx N-V employs 55 staff and has a market cap (total outstanding shares value) of 0.00.

Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

InflaRx N-V stock price (NASDAQ: IFRX)

Use our graph to track the performance of IFRX stocks over time.

InflaRx N-V shares at a glance

• Key figures

Information last updated 2022-06-25.

Latest market close	$1.52
52-week range	$0.78 - $5.69
50-day moving average more info button	$1.49
200-day moving average more info button	$2.91
Wall St. target price	$5.06
PE ratio more info button	N/A
Dividend yield more info button	$0 (0%)
Earnings per share (TTM) more info button	$-1.27

Buy InflaRx N-V shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy InflaRx N-V stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

InflaRx N-V price performance over time

Historical closes compared with the close of $1.52 from 2022-06-28

1 week (2022-06-22)	25.62%
1 month (2022-05-27)	3.40%
3 months (2022-03-29)	-34.20%
6 months (2021-12-29)	-64.65%

1 year (2021-06-29)	-48.82%
2 years (2020-06-29)	-68.53%
3 years (2019-06-28)	3.16
5 years (2017-06-25)	N/A

InflaRx N-V financials

Gross profit TTM	$0
Return on assets TTM	-26%
Return on equity TTM	-45.74%
Profit margin	0%
Book value	$2.15
Market capitalisation more info button	$34.5 million

TTM: trailing 12 months

InflaRx N-V share dividends

We're not expecting InflaRx N-V to pay a dividend over the next 12 months.

InflaRx N-V share price volatility

Over the last 12 months, InflaRx N-V's shares have ranged in value from as little as $0.776 up to $5.686. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while InflaRx N-V's is 0.8214. This would suggest that InflaRx N-V's shares are less volatile than average (for this exchange).

InflaRx N-V overview

InflaRx N. V. , a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the undisclosed chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co.

Frequently asked questions

What percentage of InflaRx N-V is owned by insiders or institutions?
Currently 14.905% of InflaRx N-V shares are held by insiders and 15.157% by institutions. How many people work for InflaRx N-V?
Latest data suggests 55 work at InflaRx N-V. When does the fiscal year end for InflaRx N-V?
InflaRx N-V's fiscal year ends in December. Where is InflaRx N-V based?
InflaRx N-V's address is: Winzerlaer Str. 2, Jena, Germany, 07745 What is InflaRx N-V's ISIN number?
InflaRx N-V's international securities identification number is: NL0012661870 What is InflaRx N-V's CUSIP number?
InflaRx N-V's Committee on Uniform Securities Identification Procedures number is: N44821101